Zinger Key Points
- The company reported a median overall survival of 15.6 months vs. 6.7-9.3 months for similar patients reported in the literature.
- Represents a substantial improvement over BriaCell's 13.4 months median overall survival previously reported in December 2023.
- Get Wall Street's Hottest Chart Every Morning
On Wednesday, BriaCell Therapeutics BCTX stock traded higher with a session volume of 113.08 million, compared to the average volume of 366.19 thousand, according to data from Benzinga Pro.
BriaCell Therapeutics announced overall survival data from its Phase 2 clinical study of Bria-IMT in combination with an immune checkpoint inhibitor (CPI) in late-stage metastatic breast cancer.
The company reported a median overall survival of 15.6 months from its most recent patients (treated since 2022) vs. 6.7-9.3 months for similar patients reported in the literature.
These patients are being treated with the same Bria-IMT formulation currently being used in BriaCell’s ongoing Phase 3 pivotal study in metastatic breast cancer.
This represents a substantial improvement over BriaCell’s 13.4 months median overall survival previously reported in December 2023.
“The Bria-IMT regimen is the only investigational drug we have seen to show these impressive survival numbers in heavily pre-treated metastatic breast cancer patients who have failed numerous prior treatments, including immune checkpoint inhibitors and antibody-drug conjugates,” stated Giuseppe Del Priore, BriaCell’s Chief Medical Officer.”
The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients (average number of prior treatments = 6) who were treated with the Bria-IMT regimen and an immune checkpoint inhibitor.
Price Action: BCTX stock is up 213.1% at $1.94 at last check Wednesday.
Read Next:
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
